CL2016002084A1 - Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina. - Google Patents

Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.

Info

Publication number
CL2016002084A1
CL2016002084A1 CL2016002084A CL2016002084A CL2016002084A1 CL 2016002084 A1 CL2016002084 A1 CL 2016002084A1 CL 2016002084 A CL2016002084 A CL 2016002084A CL 2016002084 A CL2016002084 A CL 2016002084A CL 2016002084 A1 CL2016002084 A1 CL 2016002084A1
Authority
CL
Chile
Prior art keywords
cyclopentane
substituted
compounds derived
receptor antagonists
orexin receptor
Prior art date
Application number
CL2016002084A
Other languages
English (en)
Inventor
Charlotte Fieldhouse
Angela Glen
Stephanie Maine
Tatsuhiko Fujitomo
John Stephen Robinson
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2016002084A1 publication Critical patent/CL2016002084A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

<p>COMPUESTOS DERIVADOS DE CICLOPENTANO 1,2 SUBSTITUIDOS O SUS SALES, COMO ANTAGONISTAS DEL RECEPTOR DE OREXINA; PROCESO DE PREPARACION DE DICHOS COMPUESTOS; COMPOSICION FARMACEUTICA QUE LOS COMPRENDE, UTIL PARA EL TRATAMIENTO DE ESQUIZOFRENIA Y TRASTORNOS DE PANICO, ENTRE OTROS.</p>
CL2016002084A 2014-02-20 2016-08-18 Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina. CL2016002084A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14156011 2014-02-20

Publications (1)

Publication Number Publication Date
CL2016002084A1 true CL2016002084A1 (es) 2017-09-08

Family

ID=50115776

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002084A CL2016002084A1 (es) 2014-02-20 2016-08-18 Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.

Country Status (27)

Country Link
US (3) US10011588B2 (es)
EP (1) EP3107898B1 (es)
JP (1) JP6433505B2 (es)
KR (1) KR20160121572A (es)
CN (1) CN106164047B (es)
AR (1) AR099495A1 (es)
AU (1) AU2015220551B2 (es)
CA (1) CA2938855C (es)
CL (1) CL2016002084A1 (es)
CR (1) CR20160374A (es)
EA (1) EA033758B1 (es)
EC (1) ECSP16074478A (es)
ES (1) ES2855499T3 (es)
GE (1) GEP20186910B (es)
IL (1) IL247194B (es)
MA (1) MA39152B1 (es)
MX (1) MX2016010848A (es)
MY (1) MY182564A (es)
PE (1) PE20161444A1 (es)
PH (1) PH12016501624A1 (es)
PL (1) PL3107898T3 (es)
SG (2) SG11201605298RA (es)
TN (1) TN2016000263A1 (es)
TW (1) TW201613864A (es)
UA (1) UA119552C2 (es)
UY (1) UY36003A (es)
WO (1) WO2015124932A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3093291T3 (da) 2009-10-23 2019-07-29 Janssen Pharmaceutica Nv Disubstituerede octahy-dropyrrolo [3,4-c]pyrroler som orexinreceptormodulatorer
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
HUE058759T2 (hu) 2016-03-10 2022-09-28 Janssen Pharmaceutica Nv Módszerek depresszió kezelésére orexin-2 receptor antagonisták alkalmazásával
SI3436054T2 (sl) 2016-09-13 2022-09-30 Allergan, Inc. Stabilizirani neproteinski sestavki klostridijskih toksinov
CN106580998B (zh) * 2016-12-08 2017-11-07 青岛市市立医院 一种治疗肾性高血压的药物组合物
CN107434788B (zh) * 2017-09-11 2018-06-15 威海迪素制药有限公司 一种格列吡嗪的制备方法
EP3720435B1 (en) 2017-12-05 2024-03-06 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CN112118838A (zh) 2017-12-05 2020-12-22 赛诺维信制药公司 非外消旋混合物及其用途
WO2020247627A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
KR102528677B1 (ko) * 2020-01-08 2023-05-04 주식회사 뉴로벤티 리수리드 화합물을 유효성분으로 포함하는 취약 x 증후군 또는 관련 발달 장애 치료용 조성물
CN113999142B (zh) * 2021-11-29 2023-01-24 蚌埠中实化学技术有限公司 一种手性N-Boc-反式-1,2-环己二胺的制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2148058C1 (ru) 1994-08-24 2000-04-27 Астра Актиеболаг Спиро-азабициклические соединения, способы их получения и промежуточные продукты
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
ES2319876T3 (es) 2001-05-18 2009-05-14 Astrazeneca Ab Derivados de 4 (fenil-piperazinil-metil) benzamida y su uso para el tratamiento de la ansiedad o trastornos gastrointestinales.
NZ529426A (en) 2001-06-01 2005-07-29 Astrazeneca Ab Spiroazabicyclic heterocyclic amine ligands for nicotinic acetylcholine receptors useful in therapy
HUP0400326A2 (hu) * 2001-06-28 2004-09-28 Smithkline Beecham P.L.C. Orexin receptor antagonistákként alkalmazható ciklikus N-(aril-karbonil)-amin-származékok és ezeket tartalmazó gyógyszerkészítmények
GB0130341D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
KR20040099447A (ko) 2002-04-18 2004-11-26 아스트라제네카 아베 푸릴 화합물
DE60333746D1 (de) 2002-04-18 2010-09-23 Astrazeneca Ab Thienylverbindungen
KR20040099446A (ko) 2002-04-18 2004-11-26 아스트라제네카 아베 헤테로시클릭 화합물
AU2003273179A1 (en) 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
JP2008514546A (ja) * 2004-09-30 2008-05-08 大正製薬株式会社 ピリジン誘導体及びその使用に関連する治療法
AU2006205029B2 (en) 2005-01-14 2012-09-06 Allergan, Inc. Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
EP1888563A1 (en) * 2005-05-23 2008-02-20 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
WO2008008517A2 (en) * 2006-07-14 2008-01-17 Merck & Co., Inc. Bridged diazepan orexin receptor antagonists
WO2008038841A1 (fr) 2006-09-30 2008-04-03 Japan Tobacco Inc. Dérivé de thiadiazolone et utilisation de celui-ci
WO2008071456A2 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft 3-h-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
WO2008079382A1 (en) 2006-12-21 2008-07-03 Abbott Laboratories Sphingosine-1 -phosphate receptor agonist and antagonist compounds
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
EP2176258A1 (en) * 2007-07-03 2010-04-21 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
JP5395808B2 (ja) * 2007-12-21 2014-01-22 エフ．ホフマン−ラ ロシュ アーゲー オレキシン受容体アンタゴニストとしてのヘテロアリール誘導体
JP2010155827A (ja) * 2008-12-04 2010-07-15 Takeda Chem Ind Ltd スピロ環化合物
EP2430004B1 (en) * 2009-05-12 2013-07-17 Actelion Pharmaceuticals Ltd. Novel oxazolidinone derivatives and their use as orexin receptor antagonists
US8080541B2 (en) * 2009-08-27 2011-12-20 Hoffman-La Roche Inc. Carbocyclic GlyT-1 receptor antagonists
WO2012081692A1 (ja) * 2010-12-17 2012-06-21 大正製薬株式会社 ピラゾール誘導体
KR101873083B1 (ko) * 2011-02-18 2018-06-29 이도르시아 파마슈티컬스 리미티드 오렉신 길항제로서 유용한 신규 피라졸 및 이미다졸 유도체
TWI510481B (zh) * 2012-06-04 2015-12-01 Actelion Pharmaceuticals Ltd 苯并咪唑脯胺酸衍生物
MX2015009952A (es) * 2013-02-08 2015-10-05 Celgene Avilomics Res Inc Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos.
GB201318222D0 (en) * 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GEP20186909B (en) 2014-02-20 2018-10-25 Pharmaceutical Company Limited Takeda Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
TWI651310B (zh) 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途

Also Published As

Publication number Publication date
IL247194A0 (en) 2016-09-29
GEP20186910B (en) 2018-10-25
UY36003A (es) 2015-09-30
TW201613864A (en) 2016-04-16
AU2015220551A1 (en) 2016-07-14
ECSP16074478A (es) 2018-07-31
IL247194B (en) 2019-12-31
PL3107898T3 (pl) 2021-06-14
CN106164047B (zh) 2019-04-16
EP3107898A1 (en) 2016-12-28
EA033758B1 (ru) 2019-11-22
US20170066744A1 (en) 2017-03-09
WO2015124932A1 (en) 2015-08-27
PH12016501624A1 (en) 2016-11-07
UA119552C2 (uk) 2019-07-10
CR20160374A (es) 2017-01-27
CA2938855C (en) 2022-06-21
AR099495A1 (es) 2016-07-27
SG10201908582TA (en) 2019-11-28
KR20160121572A (ko) 2016-10-19
US20180282309A1 (en) 2018-10-04
EA201691674A1 (ru) 2017-02-28
CN106164047A (zh) 2016-11-23
US10689373B2 (en) 2020-06-23
US20150232460A1 (en) 2015-08-20
PE20161444A1 (es) 2017-01-06
MA39152A1 (fr) 2017-11-30
MY182564A (en) 2021-01-25
SG11201605298RA (en) 2016-07-28
ES2855499T3 (es) 2021-09-23
CA2938855A1 (en) 2015-08-27
JP6433505B2 (ja) 2018-12-05
MA39152B1 (fr) 2019-09-30
US10011588B2 (en) 2018-07-03
TN2016000263A1 (en) 2017-10-06
US9156829B2 (en) 2015-10-13
EP3107898B1 (en) 2021-01-06
AU2015220551B2 (en) 2018-10-25
JP2017506635A (ja) 2017-03-09
MX2016010848A (es) 2017-01-23

Similar Documents

Publication Publication Date Title
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
GT201600233A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CL2017001289A1 (es) Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr).
CY1120935T1 (el) Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων
CL2016003212A1 (es) Derivados de indolín-2-ona o pirrolo-piridín-2-ona.
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
CL2015002121A1 (es) Modulares de receptores nmda de espiro-lactama y sus usos.
UY37018A (es) Inhibidores bicíclicos de pad4
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4&#39; -difluorometilo como inhibidores de la replicación de arn de la influenza.
UY36654A (es) Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
CL2015003470A1 (es) Moduladores del receptor cxcr7.
CL2017000087A1 (es) Un proceso novedoso para la purificación de rhu-gcsf
CL2016001763A1 (es) Antagonistas selectivos de nr2b
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CL2016002085A1 (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina.
CL2016002267A1 (es) Ureas asimétricas p-sustituidas y usos médicos de las mismas